

Tariq Shafi, Mbbs, Mhs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5852139/publications.pdf>

Version: 2024-02-01

118
papers

3,628
citations

117625

34
h-index

155660

55
g-index

120
all docs

120
docs citations

120
times ranked

4788
citing authors

#	ARTICLE	IF	CITATIONS
1	Time-Updated Changes in Estimated GFR and Proteinuria and Major Adverse Cardiac Events: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2022, 79, 36-44.e1.	1.9	6
2	Deoxycholic Acid and Risks of Cardiovascular Events, ESKD, and Mortality in CKD: The CRIC Study. <i>Kidney Medicine</i> , 2022, 4, 100387.	2.0	8
3	A metabolomics approach identified toxins associated with uremic symptoms in advanced chronic kidney disease. <i>Kidney International</i> , 2022, 101, 369-378.	5.2	3
4	Risk Prediction Models for Atherosclerotic Cardiovascular Disease in Patients with Chronic Kidney Disease: The CRIC Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 601-611.	6.1	8
5	Trajectories of Uremic Symptom Severity and Kidney Function in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 496-506.	4.5	13
6	Deoxycholic Acid and Coronary Artery Calcification in the Chronic Renal Insufficiency Cohort. <i>Journal of the American Heart Association</i> , 2022, 11, e022891.	3.7	2
7	Assessment of glycemia in chronic kidney disease. <i>BMC Medicine</i> , 2022, 20, 117.	5.5	6
8	Physiological Mechanisms of Hypertension and Cardiovascular Disease in End-Stage Kidney Disease. <i>Current Hypertension Reports</i> , 2022, 24, 413-424.	3.5	4
9	Quantifying Individual-Level Inaccuracy in Glomerular Filtration Rate Estimation. <i>Annals of Internal Medicine</i> , 2022, 175, 1073-1082.	3.9	32
10	Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 139-147.	0.7	18
11	Subtyping CKD Patients by Consensus Clustering: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 639-653.	6.1	41
12	Adiposity, Physical Function, and Their Associations With Insulin Resistance, Inflammation, and Adipokines in CKD. <i>American Journal of Kidney Diseases</i> , 2021, 77, 44-55.	1.9	22
13	Hospitalization Trajectories and Risks of ESKD and Death in Individuals With CKD. <i>Kidney International Reports</i> , 2021, 6, 1592-1602.	0.8	6
14	Point-of-Care Ultrasound for Evaluation of Systolic Heart Function in Outpatient Hemodialysis Units. <i>Kidney Medicine</i> , 2021, 3, 317-319.	2.0	1
15	A New Panel-Estimated GFR, Including \hat{I}^2 -Microglobulin and \hat{I}^2 -Trace Protein and Not Including Race, Developed in a Diverse Population. <i>American Journal of Kidney Diseases</i> , 2021, 77, 673-683.e1.	1.9	47
16	Patients' and family members' perspectives on arrhythmias and sudden death in dialysis: the HeartLink focus groups pilot study. <i>BMC Nephrology</i> , 2021, 22, 199.	1.8	1
17	Kidney Disease Symptoms before and after Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1083-1093.	4.5	16
18	Frailty, Age, and Postdialysis Recovery Time in a Population New to Hemodialysis. <i>Kidney360</i> , 2021, 2, 1455-1462.	2.1	5

#	ARTICLE	IF	CITATIONS
19	Abstract LB083: Characterizing colon and prostate cancers with comorbid chronic kidney disease in NHANES. , 2021, , .		0
20	Association of circulating cardiac biomarkers with electrocardiographic abnormalities in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2282-2289.	0.7	7
21	Association of tubular solute clearances with the glomerular filtration rate and complications of chronic kidney disease: the Chronic Renal Insufficiency Cohort study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1271-1281.	0.7	9
22	Contribution of "clinically negligible" residual kidney function to clearance of uremic solutes. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 846-853.	0.7	16
23	Markers of mineral metabolism and vascular access complications: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. <i>Hemodialysis International</i> , 2020, 24, 43-51.	0.9	2
24	Race and Mortality in CKD and Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2020, 75, 394-403.	1.9	22
25	Drug Selection for Treating Hypertension in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1084-1086.	4.5	1
26	Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 313-320.	1.9	39
27	Kidney Clearance of Secretory Solutes Is Associated with Progression of CKD: The CRIC Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 817-827.	6.1	42
28	Prevalence and Persistence of Uremic Symptoms in Incident Dialysis Patients. <i>Kidney360</i> , 2020, 1, 86-92.	2.1	21
29	Estimating total small solute clearance in patients treated with continuous ambulatory peritoneal dialysis without urine and dialysate collection. <i>Peritoneal Dialysis International</i> , 2020, 40, 84-92.	2.3	2
30	Performance of Indexed and Nonindexed Estimated GFR. <i>American Journal of Kidney Diseases</i> , 2020, 76, 446-449.	1.9	19
31	Indoxyl sulfate is associated with mortality after AKI " more evidence needed!. <i>BMC Nephrology</i> , 2019, 20, 280.	1.8	4
32	Development and Validation of Residual Kidney Function Estimating Equations in Dialysis Patients. <i>Kidney Medicine</i> , 2019, 1, 104-114.	2.0	9
33	Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES). <i>BMC Nephrology</i> , 2019, 20, 138.	1.8	26
34	Association of <i>FMO3</i> Variants with Blood Pressure in the Atherosclerosis Risk in Communities Study. <i>International Journal of Hypertension</i> , 2019, 2019, 1-8.	1.3	3
35	Integrative Point-of-Care Ultrasound Curriculum to Impart Diagnostic Skills Relevant to Nephrology. <i>American Journal of Kidney Diseases</i> , 2019, 73, 894-896.	1.9	9
36	Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression. <i>JAMA Internal Medicine</i> , 2019, 179, 542.	5.1	78

#	ARTICLE	IF	CITATIONS
37	Serum Metabolites and Cardiac Death in Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 747-749.	4.5	11
38	Lower levels of proteinuria are associated with elevated mortality in incident dialysis patients. <i>PLoS ONE</i> , 2019, 14, e0226866.	2.5	2
39	The Pathophysiology of Uremia. , 2019, , 273-285.e5.		0
40	Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 825-833.	0.7	37
41	Measurement and Estimation of Residual Kidney Function in Patients on Dialysis. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 93-104.	1.4	28
42	Burden and correlates of readmissions related to pulmonary edema in US hemodialysis patients: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1215-1223.	0.7	21
43	Point-of-care ultrasound education to improve care of dialysis patients. <i>Seminars in Dialysis</i> , 2018, 31, 154-162.	1.3	21
44	Metabolomics Research in Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1588-1590.	6.1	27
45	Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. <i>Scientific Reports</i> , 2018, 8, 4718.	3.3	68
46	Performance of non-traditional hyperglycemia biomarkers by chronic kidney disease status in older adults with diabetes: Results from the Atherosclerosis Risk in Communities Study. <i>Journal of Diabetes</i> , 2018, 10, 276-285.	1.8	27
47	Vascular Calcification Markers and Hemodialysis Vascular Access Complications. <i>American Journal of Nephrology</i> , 2018, 48, 330-338.	3.1	10
48	Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease. <i>Diagnostics</i> , 2018, 8, 71.	2.6	15
49	Intradialytic Activities and Health-Related Quality of Life Among Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2018, 48, 181-189.	3.1	11
50	Hematuria as a risk factor for progression of chronic kidney disease and death: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>BMC Nephrology</i> , 2018, 19, 150.	1.8	35
51	Effects of Body Size and Composition on Sex Differences in Measured GFR in a US Community-Based Older Cohort (MESA-Kidney). <i>American Journal of Kidney Diseases</i> , 2018, 72, 767-770.	1.9	3
52	Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1429-1431.	4.5	6
53	Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2017, 70, 48-58.	1.9	33
54	Residual Kidney Function: Implications in the Era of Personalized Medicine. <i>Seminars in Dialysis</i> , 2017, 30, 241-245.	1.3	19

#	ARTICLE	IF	CITATIONS
55	Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2017, 30, 251-261.	1.3	31
56	Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in the Elderly: AGES-Kidney and MESA-Kidney. <i>American Journal of Kidney Diseases</i> , 2017, 70, 406-414.	1.9	50
57	Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2017, 70, 337-346.	1.9	52
58	The Use of a Multidimensional Measure of Dialysis Adequacy—Moving beyond Small Solute Kinetics. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 839-847.	4.5	62
59	Association of Arterial Stiffness and Central Pressure With Cognitive Function in Incident Hemodialysis Patients: The PACE Study. <i>Kidney International Reports</i> , 2017, 2, 1149-1159.	0.8	15
60	Autonomic dysfunction as a mechanism of intradialytic blood pressure instability. <i>Seminars in Dialysis</i> , 2017, 30, 537-544.	1.3	19
61	Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. <i>Kidney International</i> , 2017, 92, 1484-1492.	5.2	65
62	Free and total p-cresol sulfate levels and infectious hospitalizations in hemodialysis patients in CHOICE and HEMO. <i>Medicine (United States)</i> , 2017, 96, e5799.	1.0	5
63	Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients. <i>Medicine (United States)</i> , 2017, 96, e5924.	1.0	13
64	Trimethylamine N-Oxide and Cardiovascular Events in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 321-331.	6.1	132
65	Incremental short daily home hemodialysis: a case series. <i>BMC Nephrology</i> , 2017, 18, 216.	1.8	6
66	Frequency of arrhythmia symptoms and acceptability of implantable cardiac monitors in Hemodialysis patients. <i>BMC Nephrology</i> , 2017, 18, 309.	1.8	7
67	Maintaining Patients on Home Hemodialysis: The Journey Matters as Does the Destination. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1209-1211.	4.5	7
68	Effect of a sustained difference in hemodialytic clearance on the plasma levels of p-cresol sulfate and indoxyl sulfate. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1335-1341.	0.7	29
69	Kt/Vurea and Nonurea Small Solute Levels in the Hemodialysis Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3469-3478.	6.1	51
70	Intravenous iron administration strategies and anemia management in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw316.	0.7	8
71	Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. <i>Kidney International Reports</i> , 2016, 1, 256-268.	0.8	69
72	CKD to ESRD transition: does assessment of kidney function matter?. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw327.	0.7	10

#	ARTICLE	IF	CITATIONS
73	Hemodialysis Prescription for Incident Patients: Twice Seems Nice, But Is It Incremental?. American Journal of Kidney Diseases, 2016, 68, 180-183.	1.9	19
74	Hand-carried ultrasound use in clinical nephrology. Medicine (United States), 2016, 95, e4166.	1.0	3
75	In Reply to "Plasma Clearance of Iohexol in Hemodialysis Patients Requires Prolonged Blood Sampling". American Journal of Kidney Diseases, 2016, 67, 811-812.	1.9	3
76	Association of NTproBNP and cTnl with outpatient sudden cardiac death in hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. BMC Nephrology, 2016, 17, 18.	1.8	8
77	Estimating residual kidney function in dialysis patients without urine collection. Kidney International, 2016, 89, 1099-1110.	5.2	71
78	GFR Estimation Using 125 I-Trace Protein and 125 I-Microglobulin in \hat{A} CKD. American Journal of Kidney Diseases, 2016, 67, 40-48.	1.9	121
79	Free Levels of Selected Organic Solutes and Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Results from the Retained Organic Solutes and Clinical Outcomes (ROSCO) Investigators. PLoS ONE, 2015, 10, e0126048.	2.5	75
80	Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study. BMC Nephrology, 2015, 16, 63.	1.8	23
81	Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis. American Journal of Nephrology, 2015, 42, 25-34.	3.1	41
82	The effects of weight change on glomerular filtration rate. Nephrology Dialysis Transplantation, 2015, 30, 1870-1877.	0.7	18
83	Renal Handling of 125 I-Trace Protein: Interpreting the Evidence. American Journal of Kidney Diseases, 2015, 65, 967.	1.9	4
84	Cross-sectional association of volume, blood pressures, and aortic stiffness with left ventricular mass in incident hemodialysis patients: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study. BMC Nephrology, 2015, 16, 131.	1.8	9
85	A finger photoplethysmography waveform during the valsalva maneuver detects changes in left heart filling pressure after hemodialysis. BMC Nephrology, 2015, 16, 138.	1.8	8
86	Plasma Iohexol Clearance for Assessing Residual Kidney Function in Dialysis Patients. American Journal of Kidney Diseases, 2015, 66, 728-730.	1.9	13
87	Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEciDE-ESRD study. Nephrology Dialysis Transplantation, 2015, 30, 667-675.	0.7	36
88	Intravenous Iron Exposure and Mortality in Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1930-1939.	4.5	61
89	An instrumental variable approach finds no associated harm or benefit with early dialysis initiation in the United States. Kidney International, 2014, 86, 798-809.	5.2	29
90	Predialysis Systolic BP Variability and Outcomes in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2014, 25, 799-809.	6.1	59

#	ARTICLE	IF	CITATIONS
91	Predialysis Health, Dialysis Timing, and Outcomes among Older United States Adults. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 370-379.	6.1	86
92	Non-Traditional Risk Factors are Important Contributors to the Racial Disparity in Diabetes Risk: The Atherosclerosis Risk in Communities Study. <i>Journal of General Internal Medicine</i> , 2014, 29, 290-297.	2.6	35
93	Hypertension in Hemodialysis Patients: An Opinion-Based Update. <i>Seminars in Dialysis</i> , 2014, 27, 146-153.	1.3	12
94	Troponin I and NT-proBNP and the Association of Systolic Blood Pressure With Outcomes in Incident Hemodialysis Patients: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. <i>American Journal of Kidney Diseases</i> , 2014, 64, 443-451.	1.9	16
95	Biomarkers of Vascular Calcification and Mortality in Patients with ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 745-755.	4.5	73
96	Vascular Access Type, Inflammatory Markers, and Mortality in Incident Hemodialysis Patients: The Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. <i>American Journal of Kidney Diseases</i> , 2014, 64, 954-961.	1.9	84
97	Incidental findings on cardiac computed tomography in incident hemodialysis patients: the predictors of arrhythmic and cardiovascular events in end-stage renal disease (PACE) study. <i>BMC Nephrology</i> , 2014, 15, 68.	1.8	10
98	Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 806-815.	1.9	42
99	Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators. <i>BMC Nephrology</i> , 2013, 14, 134.	1.8	50
100	Trends in anemia management in US hemodialysis patients 2004-2010. <i>BMC Nephrology</i> , 2013, 14, 264.	1.8	18
101	Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months. <i>BMC Nephrology</i> , 2013, 14, 249.	1.8	27
102	Association of Intradialytic Blood Pressure Variability With Increased All-Cause and Cardiovascular Mortality in Patients Treated With Long-term Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2013, 61, 966-974.	1.9	84
103	Serum Fructosamine and Glycated Albumin and Risk of Mortality and Clinical Outcomes in Hemodialysis Patients. <i>Diabetes Care</i> , 2013, 36, 1522-1533.	8.6	83
104	Serum β_2 -Trace Protein and Risk of Mortality in Incident Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1435-1445.	4.5	25
105	Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study. <i>BMC Nephrology</i> , 2012, 13, 167.	1.8	19
106	Comparing the association of GFR estimated by the CKD-EPI and MDRD study equations and mortality: the third national health and nutrition examination survey (NHANES III). <i>BMC Nephrology</i> , 2012, 13, 42.	1.8	35
107	Novel Markers of Kidney Function as Predictors of ESRD, Cardiovascular Disease, and Mortality in the General Population. <i>American Journal of Kidney Diseases</i> , 2012, 59, 653-662.	1.9	150
108	Polyomavirus-Associated Nephropathy. <i>Medicine (United States)</i> , 2011, 90, 296-302.	1.0	2

#	ARTICLE	IF	CITATIONS
109	In Reply to "Residual Kidney Function and Quality of Life in Incident Hemodialysis Patients". American Journal of Kidney Diseases, 2011, 57, 179-180.	1.9	0
110	Serum potassium and the racial disparity in diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Clinical Nutrition, 2011, 93, 1087-1091.	4.7	28
111	Ritonavir-induced acute kidney injury: kidney biopsy findings and review of literature. Clinical Nephrology, 2011, 75 Suppl 1, 60-4.	0.7	13
112	Association of Residual Urine Output With Mortality, Quality of Life, and Inflammation in Incident Hemodialysis Patients: The Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. American Journal of Kidney Diseases, 2010, 56, 348-358.	1.9	246
113	Serum and Dietary Potassium and Risk of Incident Type 2 Diabetes Mellitus. Archives of Internal Medicine, 2010, 170, 1745-51.	3.8	94
114	Definition and Classification of Stages of Chronic Kidney Disease: Screening for Chronic Kidney Disease. , 2010, , 81-89.		1
115	Changes in Serum Potassium Mediate Thiazide-Induced Diabetes. Hypertension, 2008, 52, 1022-1029.	2.7	122
116	Hypertension in African Americans. , 2007, , 468-481.		0
117	Determinants of Blood Pressure Response to Quinapril in Black and White Hypertensive Patients. Hypertension, 2004, 43, 1202-1207.	2.7	98
118	Management of the hospitalized injection drug user. Infectious Disease Clinics of North America, 2002, 16, 571-587.	5.1	17